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A Frailty Index Based On Deficit 
Accumulation Quantifies Mortality 
Risk in Humans and in Mice
K. Rockwood1, J. M. Blodgett1, O. Theou1, M. H. Sun2, H. A. Feridooni2, A. Mitnitski1, 
R. A. Rose3, J. Godin1, E. Gregson1 & S. E. Howlett1,2
Although many common diseases occur mostly in old age, the impact of ageing itself on disease 
risk and expression often goes unevaluated. To consider the impact of ageing requires some useful 
means of measuring variability in health in animals of the same age. In humans, this variability 
has been quantified by counting age-related health deficits in a frailty index. Here we show the 
results of extending that approach to mice. Across the life course, many important features of 
deficit accumulation are present in both species. These include gradual rates of deficit accumulation 
(slope = 0.029 in humans; 0.036 in mice), a submaximal limit (0.54 in humans; 0.44 in mice), and a 
strong relationship to mortality (1.05 [1.04–1.05] in humans; 1.15 [1.12–1.18] in mice). Quantifying 
deficit accumulation in individual mice provides a powerful new tool that can facilitate translation of 
research on ageing, including in relation to disease.
In biological systems, mortality risk typically (if not universally)1 increases with age. Even so, that risk does not 
increase uniformly. In clinical medicine, frailty, the noun, refers to this heterogeneity in risk amongst people of the 
same age2. Frail, the adjective, is used to describe those (mostly older people) at increased risk3. Understanding 
frailty is important clinically, and not just in defining who is at greatest risk. Frailty also strongly influences what 
a given disease might look like. For example, in younger people or fit older adults, a heart attack is commonly sig-
naled by chest pain. In frail older adults with a heart attack, chest pain is less common than are symptoms such as 
acute confusion, or being “generally unwell” or taking to bed4. The risk from frailty is thereby compounded by the 
adverse consequences of delay in diagnosis. Such considerations mean that understanding frailty is important in 
understanding age-related disease. Across the adult lifespan, the risk of most diseases increases with age, meaning 
that most diseases occur most often in older adults. Even so, for reasons of convention, convenience, cost and 
clarity of focus (or so it is claimed), most medical research is done on models that use young animals, which have 
not lived long enough to accumulate other health deficits5.
Under-representation of ageing is important because “the problems of old age come as a package”5,6. That pack-
age appears to influence both disease expression and disease risk. For example, in blood vessels, age-dependent 
cellular/tissue damage that goes unrepaired gives hypertension, a measurable (if asymptomatic) health deficit. 
Hypertension, in turn, increases the risk of clinically evident diseases such as chronic kidney injury, congestive 
heart failure and stroke. It is becoming clear that a range of subclinical and clinical age-related deficits, that are 
themselves not recognized as disease-specific risks, are associated with a greater chance of common age-related 
illness in older adults. One such example is the risk of dementia, which increases more in relation to the com-
bined effects of several age-related health deficits (e.g. problems with teeth, feet, bowels) than it does in relation 
to such traditional risk factors as hypertension or diabetes7. Similarly, the risk of osteoporotic fracture is more 
closely related to such age-related health deficits (known as “non-traditional risk factors”) than it is to traditional 
risk factors such as body mass index and bone mineral density8. The same is true for non-traditional risk factors 
associated with coronary heart disease hospitalization and death9. Together these results suggest that seemingly 
unrelated items which manifest as age-related health deficits might reflect more widespread processes of ageing, 
which, as they accumulate, influence late-life illness5,10. This is why it is of some consequence that the problems of 
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old age do not travel alone: to understand disease risk and expression, we must consider otherwise unmeasured 
heterogeneity in the health status of the organism/people so affected10.
To reduce unmeasured heterogeneity, we quantify how the package of age-related deficits influences the over-
all state of health. In humans we pioneered the concept of a “frailty index”. In a single variable, it measures a wide 
range of age-related health deficits (e.g. symptoms, signs, laboratory abnormalities)11–13. With a frailty index, the 
actual number of health deficits in an individual is counted and divided by the total number of potential health 
deficits that were considered, to yield a number between 0 (no deficits) and 1 (all possible deficits). For example, 
where 50 health deficits were considered (as with a health record or epidemiological survey), the frailty index 
score of someone with 5 deficits would be 5/50 = 0.10. Remarkably, even when differing health deficits, and differ-
ing numbers of health deficits are considered, their age-related accumulation shows significant stochastic dynam-
ics, which for populations give characteristic rates of increase across the life course12,14. Further, people with high 
frailty index scores are at greatly increased risk of adverse outcomes, including death12. The force of mortality 
in relation to deficit accumulation gives a limit to frailty, such that the highest value of the frailty index score is 
not the arithmetic limit of 1. Instead, people with high frailty scores cannot survive additional health deficits; in 
almost every report, > 99% of observed frailty index scores are < 0.715,16. In these ways, a frailty index based on 
deficit accumulation allows ageing itself to be investigated17. It can aid understanding for both specific age-related 
processes (e.g. cellular mechanisms related to myocyte hypertrophy18 and at larger scales, such as the health span 
response to calorie restriction or resveratrol19 or the network dynamics of ageing20).
Here, to evaluate whether quantifying deficit accumulation in humans can be translated to mice, we first 
replicated a frailty index analysis across the life course in humans. We then translated a life course frailty index 
in a naturally ageing colony of a common mouse model, the C57BL/6 strain, which we followed to extinction. 
We demonstrate similar properties of the frailty index in both humans and mice, including a characteristic distri-
bution, similar values at similar life stages, a dose-response relationship with mortality and a submaximal limit. 
These properties arise even though individual deficits vary in how they accumulate. Together, these properties of 
age-related deficit accumulation allow a better way to understand disease mechanisms in the context of the overall 
extent of ageing in given subjects, including through the use of powerful genetic interventions. The approach can 
also improve the cost-effectiveness of studying ageing animals, thereby facilitating translational research across 
a range of illnesses.
Results
Individual deficits accumulated variably in both humans and mice. Individual age-related deficits 
accumulated variably in humans of both sexes (Fig. 1A, upper panels 1–3), men only (Fig. 1B, middle panels 1–3) 
and in male mice (Fig. 1C, lower panels 1–3). Some deficits increased slowly at a near-constant rate (panels 1A1, 
1B1, 1C1). Other deficits showed negative curvature (Panels 1A2, 1B2 and 1C2) or upward curvature (Panels 1A3, 
1B3 and 1C3).
In humans and in mice the mean frailty index increased with age. In humans, the mean value of 
the frailty index increased from 0.08 ± 0.07 in younger people (20–44 years) to 0.16 ± 0.11 in the middle-aged 
(45–64 years) to 0.24 ± 0.13 in those aged 65 + years (Table 1). For men, the corresponding numbers were 
younger = 0.07 ± 0.06; middle aged = 0.14 ± 0.11 and; older = 0.23 ± 0.12. In mice, the mean for the whole set 
of observations (n = 1074) increased from 0.05 ± 0.05 in the younger mice (30–299 days) to 0.21 ± 0.04 in the 
middle-aged mice (300–599 days) to 0.29 ± 0.07 in the older mice (600 + days).
The mean value (± standard deviation) of the frailty index for all observations in humans (n = 9179) was 
0.15 ± 0.12; for men (n = 4405), the mean frailty index was 0.14 ± 0.12 (Fig. 2A,B). For mice, for all observa-
tions (n = 1032), the mean frailty index was 0.16 ± 0.12. The mean frailty index increased across the life course 
(Fig. 2C). The slope of the natural logarithm of the frailty index versus age, which has been shown to correspond 
to the rate of deficit accumulation in animals and in people12, was 0.029 in humans (0.029 in men) and 0.036 in 
mice.
In humans and mice the frailty index distribution broadened with age. The ranges differed only 
a little by age. In humans, the younger subjects’ frailty index range was 0.00–0.65 (Fig. 3, Panel A1), compared 
with 0–0.68 in the middle aged (Fig. 3, Panel A2) and 0.01–0.77 in the older group (Fig. 3, Panel A3). In men, 
the corresponding ranges were 0.00–0.55 (younger; Fig. 3, Panel B1); 0.00–0.59 (middle-aged; Fig. 3, Panel B2) 
and 0.03–0.77 (older; Fig. 3, Panel B3). The ranges in mice were 0.00–0.22 (younger; Fig. 3, Panel C1); 0.13–0.32 
(middle-aged; Fig. 3, Panel C2) and 0.16–0.55 (older; Fig. 3, Panel C3).
Even though the absolute range differed little with age, the 99% limit (i.e. the highest frailty index scores that 
encompassed 99% of the observations) showed a noticeable difference across the life course. For the younger 
groups, the 99% limit was lowest (humans = 0.35; men only = 0.34; mice = 0.18). The middle-aged groups 
showed the next largest (humans = 0.51; men only = 0.49; mice = 0.31). The largest was seen in the older groups 
(humans = 0.59; men only = 0.58; mice = 0.49). In short, the distribution of frailty index scores broadened in all 
groups with age (Fig. 3).
Greater frailty shortens survival in mice and humans. Higher frailty index scores were associated with 
reduced survival in all groups (Fig. 4; Table 2). Deficits were less lethal in women than in men, so that the survival 
for the whole human sample (Fig. 4A, Table 2) was greater than for men (Fig. 4B). Deficits were most lethal in 
mice (Fig. 4C). For all groups, more information was provided by frailty for older subjects (Fig. 4A,B,C panels 2,3) 
than for the youngest ones (Fig. 4A,B,C panel 1). The hazard ratios for mouse survival were higher for any 0.01 
frailty index increment than they were for the human samples (Table 2).
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Figure 1. Individual deficits accumulate at varying rates in people and in mice. (A) Mean scores from 
pooled data from men and women show examples of individual deficits that exhibit different patterns 
of accumulation with age (n = 9169 people). Difficulty dressing (panel 1), high blood pressure (panel 2) 
and cataract surgery (panel 3) accumulated at different rates over time. (B, panels 1, 2, 3) Rates of deficit 
accumulation were similar for men only when compared to the sample shown in A (n = 4383 men). Data 
were binned and averaged each year for A and B. (C, panels 1, 2, 3) Tumours (panel 1), gait (panel 2) and 
tremor (panel 3) are shown as examples of deficits that demonstrate different progressions with age in male 
mice. Longitudinal data for each deficit were obtained from the entire cohort of mice and binned in 100 day 
increments (n = 251 mice).
HUMANS Overall Younger 20–44 years
Middle-aged 
45–64 years Older 65+ years
N 9169 4083 2642 2444
N Males 4383 1867 1292 1242
Mean FI 0.15 ± 0.12 0.08 ± 0.07 0.16 ± 0.11 0.24 ± 0.13
Range 0–0.77 0.00–0.65 0.00–0.68 0.01–0.77
99th Percentile 0.54 0.35 0.51 0.59
MICE Overall Younger 30–299 days
Middle-aged 
300–599 days Older 600+ days
N 251 251 229 158
N Observations 1032 495 228 309
Mean FI1 0.16 ± 0.12 0.05 ± 0.05 0.21 ± 0.04 0.29 ± 0.07
Range 0–0.55 0–0.22 0.13–0.32 0.16–0.55
99th Percentile 0.44 0.18 0.31 0.49
Table 1.  Summary statistics for the human and mouse cohorts. 1Values represent the mean ± SD.
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Discussion
If research on the diseases of ageing is lagging by neglecting the other problems that come with age5,6, any remedy 
requires that those other problems be quantified17,21,22. Here we have shown that such a quantitative measure, a 
clinical frailty index based on health deficit accumulation, can be translated into mice and used to follow them 
Figure 2. Mean ± SD frailty index (FI) scores increase at similar rates in people and in mice. (A) Data 
from 46 individual deficits were used to calculate a FI score for each person. FI scores increased with age in 
the pooled sample of men and women (n = 9169). Data were binned in one year increments and FI scores 
were averaged at each age. (B) Similar results were seen in men only, using the same increments, averages and 
binning (n = 4383). (C) An FI score was calculated from 31 individual mouse deficits for all 251 mice. Data 
were binned in 100 day increments and FI scores were averaged for each age group (± SD). In each panel, the 
essential idea of frailty – unmeasured heterogeneity in the health status of organisms of the same age – is evident 
in the standard deviations. Even so, the fits to a linear model for the mean values were r2 = 0.97 for humans, 0.96 
for men only and 0.93 for mice. The fits to an exponential model were r2 = 0.98 for humans, 0.96 for men only 
and 0.87 for mice. All the fits were significant for p < 0.0001.
www.nature.com/scientificreports/
5SCieNtifiC REPORtS | 7:43068 | DOI: 10.1038/srep43068
across the life course; this last was endorsed as greatly preferable in a recent multidisciplinary report21. The mouse 
frailty index showed several essential features seen with human ageing. Although individual deficit accumu-
lation patterns varied, the distribution of the frailty index broadened with age and mean deficit accumulation 
increased. At all ages, greater deficit accumulation was associated with reduced survival in age-adjusted models. 
The frailty index approach offers a probe by which the impact of individual problems can be understood in the 
context not just of chronological ageing, but of the increased hazard that goes with greater deficit accumulation23. 
The approach has been extended to demonstrate that, across a spectrum from subcellular to clinically detect-
able changes, frailty correlates with the degree of myocyte hypertrophy and contractile dysfunction18 as well 
as sinoatrial node dysfunction, myocardial interstitial fibrosis and altered expression of matrix metalloprotein-
ases24 in the ageing heart. Given the potential repurposing of existing, approved medications such as rapamycin 
and metformin25, and pending the development of a comprehensive system of ageing biomarkers26, it also is 
a ready-made candidate for understanding how interventions to modify aspects of ageing processes might be 
Figure 3. Mean frailty index (FI) scores increased and their distribution broadened with age in humans 
and in mice. (A) Frequency distributions of FI scores for younger (20–44 years; panel 1), middle-aged (45–64 
years; panel 2) and older people (65 + years; panel 3) are illustrated. The frailty distribution moved right and 
broadened with age. (B, panels 1, 2, 3) Results were similar in men only when compared to the pooled sample 
shown in A. (C, panels 1, 2, 3) Frequency distributions of the FI scores for male mice also shifted to the right 
and broadened with increasing age. Data were stratified by age into three groups; younger (30–299 days old, 
panel 1), middle-aged (300–599 days old, panel 2) and old mice (600+ days old, panel 3).
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evaluated27. A parallel approach and terminology can also facilitate clinician – researcher interactions, the relative 
lack of which is seen as an important barrier in translational research in ageing28.
Employing a frailty index can facilitate insights into how ageing works. Here, even amongst mice of similar 
genetic backgrounds, raised under similar circumstances, the level of deficit accumulation varied. Reflected in 
Figure 4. High frailty index (FI) scores predict mortality at all ages both in humans and in mice. (A) Kaplan 
Meier survival curves stratified by 0.1 increments of the FI for younger (20–44 years; panel A1, n = 4083), 
middle-aged (45–64 years; panel A2, n = 2642) and older people (65+ years; panel A3, n = 2444) are illustrated. 
At any age, higher frailty scores were associated with reduced survival. (B) Results were similar for men, 
(younger, Panel B1, n = 1867, middle-aged, Panel B2, n = 1292, older, Panel B3, n = 1242) although mortality 
was higher in men than in the whole human sample. (C) Kaplan Meier survival curves were also constructed 
for younger (30–299 days; panel C1, n = 251), middle-aged (300–599 days; panel C2, n = 229) and older (600+ 
days; panel C3, n = 158) mice. Each mouse is represented only once in each age stratum. In general, as FI scores 
increased survival declined in all three age groups of mice. Mortality was high in one FI stratum in the older 
group (e.g. FI = 0.1–0.2). This reflected a small number of very old mice with low FI scores and severe deficits 
that required immediate euthanasia.
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7SCieNtifiC REPORtS | 7:43068 | DOI: 10.1038/srep43068
the broadening of the distribution of the frailty index with age, the stochasticity of frailty dynamics is significant 
as deficits accumulate20. Given that some degree of deficit accumulation is reversible29, understanding factors that 
allow deficits to decrease, even in old age, is important.
A 2016 report showed that the increase in deficit accumulation can be modelled solely on the basis of deficit 
interaction, without invoking time-dependent damage20 as has classically been done in studying age and mor-
tality30,31. Here, deficits were both relatively higher and more lethal in mice, suggesting that their interactions 
are more damaging. If we accept that the accumulation of deficits reflects damage that goes unremoved or unre-
paired20,29 then it follows that, even in an animal care facility environment in which the animals are relatively 
protected from predation, greater levels and lethality of age-related deficits likely reflect differences in investment 
in repair between mice and people.
A frailty index is especially useful in increasing the amount of data that can be collected on ageing animals. 
The high cost of ageing research reflects in part that unexpected death results in no data being available on that 
animal. In contrast, tracking frailty scores can allow at least some features of age-related change associated with 
specific conditions to be investigated, even when animals die ahead of planned experimental evaluation. Where 
death occurs before an experiment can be conducted, frailty index data can be compared with necropsy findings.
Our data must be interpreted with caution. The human data included men and women. The mouse data are for 
males only. We recognize the great virtue in studying ageing and frailty in female animals32; some data collection 
with female mice is ongoing and we plan to collect more. We also lack data on very frail mice (e.g. the 99% frailty 
index limit was 0.44) compared with very frail people. This reflects good animal husbandry practices. Indeed, we 
were intrigued that the veterinarians and animal care attendants who observed the mice, but who did not score a 
frailty index, the animals which they identified as needing to be sacrificed due to age-related debility had frailty 
index scores between 0.50–0.54. Tracking changes in the degree of deficit accumulation might provide some 
remedy against unexpected death and loss of animals before planned experiments. The designs of the two data 
sources are also different. The mouse data represent a small cohort followed to extinction, whereas we have only 
cross-sectional data with necessarily time-limited mortality follow-up on the humans, albeit with a much larger 
sample size. We attempted to mitigate the small mouse sample size by multiple observations. We were careful not 
to double-count mice in the same age range.
Translation here was from human studies that then were employed in mice. “Back translation” is now under 
way. The version of the mouse frailty index used here was modelled on a comprehensive geriatric assessment, and 
is suitable for longitudinal use. In contrast, the initial mouse frailty index chiefly used laboratory test data, arising 
in the context of terminal experiments18. More recently, we have developed a version of the frailty index for use 
in humans that employs only laboratory test data, as a means of understanding subclinical aspects of frailty33,34. 
Frailty is also now a target for treatment in and of itself35, arguing further for integrative methods for its measure-
ment. For these reasons, combining the clinical and laboratory-based versions, in both humans and in mice, is 
motivating additional inquires by our group.
Methods
Study design and sample: mice. Two hundred fifty-seven male C57BL/6J mice were purchased from 
Charles River Laboratories (St. Constant, Quebec) at 3 to 4 weeks of age. Six mice died before any frailty assess-
ments were completed, so these mice were excluded from the analysis for a final sample size of 251 mice (Table 1). 
Mice were housed in the Carleton Animal Care Facility in groups of three to five mice per microisolator cage and 
followed throughout their lives in a longitudinal study. They were kept on a 12-hour light/dark cycle and had free 
access to water and food (ProLab RMH 3500, Purina LabDiet, Aberfoyle, Ontario, Canada). Animal protocols 
followed the Canadian Council on Animal Care Guide to the Care and Use of Experimental Animals (CCAC, 
Ottawa, ON: Vol. 1, 2nd ed. 1993; Vol. 2, 1984) and were approved by the Dalhousie University Committee on 
Laboratory Animals. No randomisation was used. For all experiments, the investigator knew the age of the ani-
mal, but not its current or prior frailty scores.
Human - Age and Sex-Adjusted Model
 Full sample
Age group
20–44 years 45–64 years 65+ years
Frailty 




(1.04–1.05) (1.07–1.11) (1.05–1.07) (1.05–1.06)
Mice - Time-Dependent Covariate Analysis
 Full sample
Age group
30–299 days 300–599 days 600+ days
Frailty 
index 1.15 1.27 1.07 1.17
mice (per 
0.01) (1.12–1.18) (1.05–1.52) (1.01–1.14) (1.14–1.21)
Table 2.  COX regression analysis of relationship between frailty and mortality for humans and for mice.
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Study design and sample: humans. Secondary data for the human sample were acquired from the 
National Health and Nutrition Examination Survey (NHANES), a series of cross-sectional surveys investigating 
the health status of a nationally representative sample with examination, questionnaire and laboratory data36. 
Here, the 2003–2004 and 2005–2006 cohorts were amalgamated to give 20470 potential participants, of whom 
10020 individuals were aged 20 and older. Of these 10020, we excluded 841 subjects due to missing frailty data 
and 10 additional subjects with missing mortality data for a final sample size of 9169 (Table 1). Criteria for a valid 
frailty score are detailed below. The NHANES survey protocol was approved by the National Center for Health 
Statistics Research Ethics Review Board of the Centers for Disease Control and Prevention, Protocol 98–12 for 
the 2003–2004 sample and Protocol 2005–2006 for the 2005–2006 cohort37. All participants provided written 
informed consent. All methods were performed in accordance with the Declaration of Helsinki regarding ethical 
standards for research involving human subjects.
Data availability. Data were accessed through a public access data file available on the NHANES website 
http://www.cdc.gov/nchs/nhanes.htm36. Follow up mortality data were available using public-use linked mortal-
ity files, where mortality assessment was based on a probabilistic match between the NHANES records and the 
death certificate records of the National Death Index using available identifying information (i.e., Social Security 
Number, first name, middle initial, last name, month of birth, year of birth, day of birth, sex, father’s surname, 
state of birth, race, state of residence, marital status) (http://www.cdc.gov/nchs/ndi/index.htm)38. Time to death 
was calculated using person years of follow-up from the examination date until date of death or until the subject 
was censored on December 31st 2011. The datasets generated and/or analysed during the current study are avail-
able from the corresponding author on reasonable request.
Frailty index construction in humans. The frailty index, as originally developed for use in humans, oper-
ationalizes frailty by dividing the number of deficits in an individual by the total number of deficits considered39. 
Here, the human frailty index comprised 46 deficits. All deficits were coded so that the presence of a deficit 
was scored as 1 and its absence was scored as 0. For variables with an intermediate response, a score of 0.5 was 
assigned. The frailty index was calculated by dividing the number of deficits present by the total number of deficits 
considered. For example, a subject with 25 of a possible 50 deficits would have a frailty index score of 25/50 = 0.5 
A score of 0 represents full health, whereas a score of 1 represents a theoretical ‘complete’ frailty.
The human frailty index has been validated previously in the NHANES population40. A complete list of the 
deficits, procedures used and the coding guide has been published elsewhere40. Briefly, to be included in a frailty 
index, a deficit must meet the following criteria39: (1) it must increase with age; (2) it must be health-related; (3) 
it must be present in at least 1% of the study population; (4) it must not be present in 80% of the study population 
before age 80; (5) it must not be missing in more than 5% of the study population. Continuous variables were 
coded using cut-points proposed in the literature, as described in our previous work34. Empirically, > 99% of 
people have frailty index scores < 0.715. A frailty score was only calculated for participants in whom < 20% of the 
variables were missing. To calculate the frailty index in those missing fewer than 20% of variables, the denomina-
tor was reduced to reflect the number of available variables.
Frailty index construction in mice. Our group has adapted this method to create a frailty index tool based 
on the accumulation of clinically apparent health deficits in naturally ageing mice41,42. A published checklist41,42 
was used to evaluate 31 parameters that assessed deficits in the integument, musculoskeletal system, vestibulo-
cochlear and auditory systems, ocular and nasal systems, digestive system, urogenital system, respiratory sys-
tem and signs of discomfort. Mice were also weighed and body surface temperature measured with an infrared 
probe (Infrascan; La Crosse Technology). Body weight (g) and body surface temperature (°C) were scored based 
on deviation from the study average for that age and described previously41,42. Frailty was assessed at approxi-
mately 1, 6, 12 and 18 months and at varying ages thereafter. We also recorded the time to death for each mouse. 
Mortality occurred when animals either died suddenly or were euthanized due to illness.
Statistical analysis. Statistical analyses were conducted using SPSS 20, R 3.2.4, MatLab and SigmaPlot. An 
alpha level of 0.05 was used to determine statistical significance. Demographic characteristics of the sample were 
expressed using mean frailty index scores ± SD, range (min and max) and 99th percentiles. The 99% limit was 
defined as the highest frailty index score that encompassed 99% of the observations. The association between age 
and the prevalence of selected individual deficits were graphed for mouse and human data. Density distribution 
curves were created for all frailty index scores. Curve estimation was used to assess the relationship between age 
and frailty score. To examine frailty across the life course, analyses were stratified by age group (20–44, 45–64, 
65 + years of age for humans; 30–299, 300–599, 600+ days for mice). For the mouse frailty measurements, which 
were longitudinal, each mouse is represented only once in each age stratum, with the exception of the Cox regres-
sion described below. To investigate the classification and predictive ability of the frailty index score on mortality, 
we employed AUCs and age- and sex-adjusted Cox regression models. For the mouse data, frailty was treated as a 
time-dependent covariate in Cox regressions. Time was used as a time-variable in the Cox model. For these Cox 
regression models, power was high for both the mice data and the human data (1-beta > 0.95 at alpha < 0.05). 
Time intervals were created based on the time between the relevant frailty assessment and the death of each 
mouse. Obviously, each mouse death can be counted only once, but each mouse was assessed over their life 
span. The frailty index at the beginning of each age interval (young, middle-aged, old) was related to survival 
within that interval. Each hazard ratio represents the increased risk of mortality for every 0.01 increase in frailty 
index score. For the analysis by age group, a variable was calculated for each of the three age groups (i.e., 30–299, 
300–599, 600+ ). Similar to a dummy variable, when the young group was the target, each mouse was represented 
by its frailty index value for time intervals ending at < 300 days; values higher than this were scored as 0. Similarly, 
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when the target was middle age, each mouse between 300 and 599 days was represented by its frailty index score, 
and was scored 0 otherwise. Likewise, the old variable had the corresponding frailty index values for intervals 
> 600 days and was scored 0 otherwise. The three variables were included in a single Cox regression. Kaplan Meier 
survival curves demonstrated differences in mortality rates between frailty groups.
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